Effect of transcutaneous electrical acupoint stimulation on postoperative gastrointestinal dysfunction after laparoscopic urological surgery
Official title: The Effect of Transcutaneous Electrical Acupoint Stimulation on Postoperative Gastrointestinal Dysfunction After Urological Laparoscopic Surgery
Run by The First Affiliated Hospital of Xiamen University · NCT07133620 · Data updated 2026-11-12
This study tests whether placing small electrical pulses on acupuncture points after laparoscopic urological surgery can help reduce postoperative GI problems and checks that it is safe.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 112 (estimated) |
| Sponsor | The First Affiliated Hospital of Xiamen University Academic / other |
| Locations | 1 site (Xiamen, Fujian) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | November 1, 2026 |
| Study ends | November 30, 2026 |
| Registry record updated | June 24, 2026 |
| Trial ID | NCT07133620 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 undergoing laparoscopic urological procedures (e.g., nephrectomy, radical prostatectomy) with ASA I–III, able to consent and complete questionnaires.
✕Probably not a fit
Patients with significant cardiovascular, pulmonary, or cerebrovascular disease, recent GI motility drug use, TEAS contraindications, or prior TEAS/electro-acupuncture treatment may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional trial examines transcutaneous electrical acupoint stimulation (TEAS) as a potential approach to postoperative gastrointestinal dysfunction (POGD) following laparoscopic urological procedures under general anesthesia. Participants are randomized to receive TEAS or sham TEAS before and after surgery, with GI symptoms and relevant biological markers tracked for up to five days postoperatively. The study aims to understand both the effectiveness and the safety of TEAS and to explore possible mechanisms for its effects. Eligible adults include those undergoing specified laparoscopic urological surgeries with ASA I–III, while those with certain medical conditions or prior TEAS use are excluded. The trial is led by The First Affiliated Hospital of Xiamen University and conducted at that site.
Why it matters
Potential benefit: If successful, TEAS could offer a nonpharmacologic option to reduce postoperative GI dysfunction and improve recovery after laparoscopic urological surgery.
How similar studies have gone: Previous studies in related fields suggest TEAS can influence postoperative recovery, but data specific to GI function after urological laparoscopy are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * BMI \< 28 kg/m2 * ASA classification is I-III grade * Laparoscopic urological procedures under general anesthesia, including but not limited to laparoscopic nephrectomy and laparoscopic radical prostatectomy for prostate cancer * Normal comprehension ability, and the patient or his/her family members can cooperate in filling out the questionnaire * Voluntary to sign the informed consent form Exclusion Criteria: * Comprehensive assessment of severe cardiovascular, pulmonary and cerebrovascular diseases (such as severe coronary heart disease, valve diseases, respiratory failure, cerebral hemorrhage, cerebral infarction, etc.) * Preoperative use of analgesic and gastrointestinal motility drugs * TEAS contraindications (having electronic devices in the body, skin damage or infection at the stimulation site) * Previous history of TEAS or electro-acupuncture treatment * Previous history of gastrointestinal surgery, long-term gastrointestinal motility disorders and severe intestinal diseases * Pregnancy
Where it's running
-
The First affiliated Hospital of Xiamen University
Xiamen, Fujian, China Recruiting
Study contacts
- Study coordinator: Linhong Wang
- Email: 2797424071@qq.com
- Phone: +86-13807548496
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-XHER2 PET/CT imaging to see HER2 in solid tumors
A noninvasive PET/CT imaging test using 68Ga-XHER2 is being tried to see if it reflects HER2 levels in solid tumors.
-
68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery
This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.
-
Anxiety and Depression in Patients with Hematologic Cancers
This study tests whether anxiety and depression levels before and after treatment are linked to treatment outcomes in people newly diagnosed with lymphoma, multiple myeloma, or leukemia.
-
VCC combination in relapsed or refractory AML
A group of adults with relapsed or refractory AML will receive a three-drug combo (venetoclax, chidamide, and chiglitazar sodium) to see if it helps control the leukemia.
-
Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL
This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.